New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Acrivon Therapeutics, Inc

Contributing Author

Recent Articles by Acrivon Therapeutics, Inc

Mar-19	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights ACRV GlobeNewswire
Mar-17	Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors ACRV GlobeNewswire
Feb-24	Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference ACRV GlobeNewswire
Feb-23	Key Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress ACRV GlobeNewswire
Feb-18	Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory ACRV GlobeNewswire
Jan-23	Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress ACRV GlobeNewswire
Jan-08	Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 ACRV -34.58% GlobeNewswire
Jan-06	Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast ACRV +31.44% GlobeNewswire
Dec-17	UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast ACRV GlobeNewswire
Dec-17	Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates ACRV GlobeNewswire
Nov-13	Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights ACRV -9.21% ACRV +8.21% GlobeNewswire
Oct-22	Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference ACRV GlobeNewswire
Oct-01	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ACRV GlobeNewswire
Aug-13	Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights ACRV +6.11% ACRV GlobeNewswire
May-14	Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights ACRV GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)